Robert Meisner, MD

Psychiatric Neurotherapeutics Program, McLean Hospital, Belmont, Massachusetts; Acute Psychiatric Service, Massachusetts General Hospital, Boston, Massachusetts

  • 1Article
  • 5.1KReads1
  • 2025Active
  • 8Collaborators
  • 6Citations2

1 Read counts for articles published before 2020 may include some non-human traffic.

2 Citation counts provided by Crossref.

About

Robert Meisner, MD, is affiliated with the Psychiatric Neurotherapeutics Program at McLean Hospital and the Acute Psychiatric Service at Massachusetts General Hospital. His work, published in 2025, focuses on treatment-resistant depression, specifically comparing repeated ketamine infusion and intranasal esketamine. He has collaborated with co-authors including Amanda Sedgewick, Brian Boyle, Courtney Miller, Danika Dai, and Paula Bolton.

Publications

JCP
Comparative Effects of Repeated Ketamine Infusion vs Intranasal Esketamine in Patients with Treatment Resistant Depression: A Retrospective Chart Review
Original Research

Comparative Effects of Repeated Ketamine Infusion vs Intranasal Esketamine in Patients with Treatment Resistant Depression: A Retrospective Chart Review

September 22, 2025

In this naturalistic sample of patients with similarly severe treatment resistant depression treated over a 4- to 5-week induction period, intravenous racemic ketamine was associated with more rapid response...
, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Ketamine and Psychedelics

Listen to the Podcast
The Journal of Clinical Psychiatry podcast cover with Benjamin Brody, MD

Subscribe to read
more articles

Subscribe